Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 731-739

  Schneider, J S ^a   Tinker, John P ^a   Van Velson, Maria ^a   Menzaghi, Frederique ^b   Lloyd, G Kenneth ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; LEVODOPA; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERM EXPOSURE; MACACA; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT TERM MEMORY; TASK PERFORMANCE; VISUAL MEMORY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ATTENTION; COGNITION DISORDERS; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOPAMINE AGENTS; FEMALE; LEVODOPA; MACACA FASCICULARIS; MACACA NEMESTRINA; MALE; MEMORY, SHORT-TERM; NICOTINE; NICOTINIC AGONISTS; PATTERN RECOGNITION, VISUAL; PYRIDINES; PYRROLIDINES; RECEPTORS, NICOTINIC; SPACE PERCEPTION;

EID: 0032808086     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Arnsten AFT, Cai JX and Goldman-Rakic PS (1988) The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypertensive effects: Evidence for alpha-2 receptor subtypes. J Neurosci 8:4287-4298.
2. Arnsten AFT and Contant TA (1992) Alpha-2 adrenergic agonists decrease distractibility in aged rhesus monkeys performing the delayed response task. Psychopharmacology 108:159-169.
3. Baron JA (1986) Cigarette smoking and Parkinson's disease. Neurology 36:1490-1496.
4. Battig K, Rosvold HE and Mishkin M (1960) Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys. J Comp Psychol 53:400-404.
5. Brozoski T, Brown RM, Rosvold HE and Goldman PS (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science (Wash DC) 205:929-931.
6. Buccafusco JJ and Jackson WJ (1991) Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12:233-238.
7. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P and Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 116:1701-1725.
8. Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK and McDonald IA (1996) (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): A novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 39:3235-3237.
9. Diamond A (1990) Developmental time course in human infants and infant monkeys, and the neural basis of inhibitory control in reaching. Ann NY Acad Sci 608:637-669.
10. Diamond A (1996) Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philos Trans R Soc Lond B Bid Sci 351:1483-1493.
11. Divac I, Rosvold HE and Szarcbart MK (1967) Behavioral effects of selective ablation of the caudate nucleus. J Comp Physiol Psyckol 63:184-190.
12. Downes JJ, Roberts AC, Sahakian BJ, Evenden JI, Morris RG and Robbins TW (1989) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction. Neuropsychologia 27:1329-1343.
13. Elrod K, Buccafusco JJ and Jackson WJ (1988) Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43:277-287.
14. Fagerstrom KO, Pomerleau O, Giordani B and Stelson F (1994) Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 116:117-119.
15. Flowers KA and Robertson C (1985) The effect of Parkinson's disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatr 48:517-529.
16. Gotham AM, Brown RG and Marsden CD (1988) "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 111:299-321.
17. Ishikawa A and Miyatake T (1993) Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 117:28-32.
18. Jackson WJ, Prendergast MA, Buccafusco JJ, Decker MW and Americ SP (1997) CNS nicotinic receptor agonists prevent distractibility in non-human primates. Soc Neurosci Abstr 23:216.
19. Jones GMM, Sahakian BJ, Levy R, Warburton DM and Gray JA (1992) Effects of nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
20. Knipper M, Berzaghi MDP, Blochl A, Breer H, Thoenen H and Lindholm D (1994) Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur J Neurosci 6:668-671.
21. Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML and Gironell A (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 119:2121-2132.
22. Lange KW, Robbins TW, Marsden CD, James M, Owen AM and Paul GM (1992) L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 107:394-404.
23. Lapchak PA, Araujo DM and Hefti F (1993) Cholinergic regulation of hippocampal brain-derived neurotrophic factor expression: Evidence from lesion and chronic cholinergic drug treatment studies. Neuroscience 52:575-585.
24. Lees AJ and Smith E (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106:257-270.
25. Levin BE, Llabre MM and Weiner WJ (1989) Cognitive impairments associated with early Parkinson's disease. Neurology 39:557-561.
26. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE and March J (1995) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123:55-63.
27. Menzaghi F, Sacaan AI, Reid RT, Santori EM, Correa LD, Adams P, Whelan KT, Risbrough VB, Rao TS, Schneider JS and Lloyd GK (1996) Characterization of SIB-1508Y, the active enantiomer of a novel nicotinic acetylcholine receptor (NAChR) agonist, SIB-1765F. Soc Neurosci Abstr 22:1523.
28. Menzaghi F, Whelan KT, Risbrough VB, Rao TS and Lloyd GK (1997a) Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther 280:384-392.
29. Menzaghi F, Whelan KT, Risbrough VB, Rao TS and Lloyd GK (1997b) Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-dopa in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther 280:393-401.
30. Moll H (1926) The treatment of post-encephalitic parkinsonism by nicotine. Br Med J 1:1079-1081.
31. Morens DM, Grandinetti A, Reed D, White LR and Gross GW (1995) Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology 45:1041-1051.
32. Morris RG, Downes JJ, Sahakian BJ, Evenden JL, Heald A and Robbins TW (1988) Planning and spatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatr 51:757-766.
33. Murphy BL, Arnsten AFT, Goldman-Rakic PS and Roth RH (1996a) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93:1325-1329.
34. Murphy BL, Arnsten AFT, Jentsch JD and Roth RH (1996b) Dopamine and spatial working memory in rats and monkeys: Pharmacological reversal of stress-induced impairment. J Neurosci 18:7768-7775.
35. Owen AM, Beksinka M, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Sahakian BJ and Robbins TW (1993a) Visuo-spatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 31:627-644.
36. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW and Robbins TW (1992) Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 118:1727-1751.
37. Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald LA, Rao TS and Lloyd GK (1997a) Pharmacological characterization of SIB-1765F: A novel cholinergic ion channel agonist. J Pharmacol Exp Ther 280:373-383.
38. Sacaan AI, Santori EM, Keegan M, Lloyd GK and Rao TS (1997b) Dopamine (DA) and norepinephrine (NE) release in the prefrontal cortex (PFC) are regulated by different nAChR subtypes. Soc Neurosci Abstr 23:1200.
39. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M and Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 111:695-718.
40. Schneider JS (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534:25-36.
41. Schneider JS and Kovelowski CJ (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519:122-128.
42. Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F and Lloyd GK (1998a) Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord 13:637-642.
43. Schneider JS and Roeltgen DP (1993) Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res 615:351-354.
44. Schneider JS, Sun Z-Q, Roeltgen DP (1994a) Effects of dihydreridine, a full dopamine D1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res 663:140-144.
45. Schneider JS, Sun ZQ and Roeltgen DP (1994b) Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys. Pharmacol Biochem Behav 48:235-240.
46. Schneider JS, Unguez G, Yuwiler A, Berg S and Markham CH (1988) Deficits in operant behavior in monkeys treated with MPTP. Brain 111:1265-1285.
47. Schneider JS, Van Velson M, Menzaghi F and Lloyd GK (1998b) Treatment with the nicotinic acetylcholine receptor agonist SIB-1508Y improves object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment. Ann Neurol 43:311-317.
48. Sharpe MH (1990) Distractibility in early Parkinson's disease. Cortex 26:239-246.
49. Sharpe MH (1992) Auditory attention in early Parkinson's disease: An impairment in focused attention. Neuropsychologia 30:101-106.
50. Terry AV and Clarke MSF (1994) Nicotine stimulation of nerve growth factor receptor expression. Life Sci 55:91-98.